Stocktoria
Embecta Corp. EMBC
Embecta Corp. (EMBC) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the grey zone. It pays a dividend yielding 16.90% (safety: safe). FY2025 revenue was $1.1B at a 8.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.339 |
| Retained earnings / assets | -0.408 |
| EBIT / assets | 0.222 |
| Equity / liabilities | -0.374 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| EMBC | Embecta Corp. | 6/9 | 1.99 | 2.2 | -3.8% |
| TNDM | TANDEM DIABETES CARE INC | 3/9 | -3.04 | — | +7.9% |
| INSP | Inspire Medical Systems, Inc. | 6/9 | 9.88 | 9.1 | +13.6% |
| HAE | HAEMONETICS CORP | 7/9 | 2.85 | 36.1 | -2% |
| OFIX | Orthofix Medical Inc. | 5/9 | 1.02 | — | +2.9% |
| ATEC | Alphatec Holdings, Inc. | 6/9 | -4.63 | — | +25% |
| PEN | Penumbra Inc | 6/9 | 8.59 | 70.1 | +17.5% |
About Embecta Corp.
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
FAQ
Is EMBC financially healthy?
Embecta Corp.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does EMBC pay a dividend, and is it safe?
Yes. Embecta Corp. pays a dividend yielding about 16.90% with a 36.7% payout ratio, rated “safe” for safety.
How profitable is EMBC?
In FY2025, Embecta Corp. had a net margin of 8.8%.
Is EMBC overvalued or undervalued?
Embecta Corp. trades at about 2.9× trailing earnings — below its 10-year norm (10-year range 7.9×–12.4×, median 10.5×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for EMBC?
The average Wall-Street price target for Embecta Corp. is $4.00, about 15.8% below the recent price, from 2 analysts.
Is EMBC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Embecta Corp.: a Piotroski F-score of 6/9, an Altman Z″ in the grey zone, a P/E of about 2.2×, a dividend yield of 16.90%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.